| (+)-Theta-cypermethrin |
|
|
|
|
|
| (+)-Tyrphostin B44 |
|
|
|
|
97.04% |
| (3S)-Tanzisertib hydrochloride |
|
|
|
|
|
| (3S,4S)-PF-06459988 |
|
|
|
|
98.97% |
| (E)-AG 556 |
|
|
|
|
99.91% |
| (E)-AG 99 |
|
|
|
|
98.36% |
| (E/Z)-Afatinib |
|
|
|
|
99.98% |
| (E/Z)-AG490 |
|
|
|
|
99.71% |
| (E/Z)-CP-724714 |
|
|
|
|
|
| (R)-Afatinib |
|
|
|
|
|
| (R)-DZD1516 |
|
|
|
|
98.80% |
| (Rac)-8-Gingerol |
|
|
|
|
|
| (Rac)-JBJ-04-125-02 |
|
|
|
|
|
| (Rac)-JBJ-04-125-02 acetate |
|
|
|
|
96.58% |
| (S)-Sunvozertinib |
|
|
|
|
99.05% |
| (Z)-RG-13022 |
|
|
|
|
|
| (Z)-Tyrphostin A51 |
|
|
|
|
|
| 1,2,3,4-Tetrahydro Staurosporin |
|
|
|
|
|
| 1-Methyl-1H-pyrrolo[2,3-b]pyridine |
|
|
|
|
|
| 13(S)-HPODE |
|
|
|
|
95.05% |
| 2′-Thioadenosine |
|
|
|
|
|
| 2-2(t) aptamer sodium |
|
|
|
|
99.28% |
| 4(3H)-Quinazolinone |
|
|
|
|
99.89% |
| 4,7-Dihydroxycoumarin |
|
|
|
|
98.25% |
| 4-DAMP |
|
|
|
|
99.96% |
| 4-TCPA |
|
|
|
|
|
| 4-Methyl erlotinib |
|
|
|
|
99.34% |
| 4-Epidoxycycline |
|
|
|
|
|
| 8-Gingerol |
|
|
|
|
99.82% |
| Ruserontinib |
|
|
|
|
99.32% |
| A2AR/EGFR-IN-1 |
|
|
|
|
|
| ADCT-701 Antibody |
|
|
|
|
|
| ADS103317 |
|
|
|
|
|
| AEE788 |
|
|
|
|
98.39% |
| AfaPhos1 |
|
|
|
|
|
| Afatinib impurity 11 |
|
|
|
|
99.10% |
| Afatinib oxalate |
|
|
|
|
|
| AFM24 |
|
|
|
|
96.26% |
| AG 1406 |
|
|
|
|
99.03% |
| AG 555 |
|
|
|
|
98.0% |
| AG-494 |
|
|
|
|
98.69% |
| AG-825 |
|
|
|
|
98.13% |
| AG1557 |
|
|
|
|
99.54% |
| AG490 |
|
|
|
|
99.86% |
| AGW-11 |
|
|
|
|
|
| ALK-IN-1 |
|
|
|
|
99.94% |
| ALK/EGFR-IN-1 |
|
|
|
|
|
| ALK/EGFR-IN-1-d5 |
|
|
|
|
|
| Allitinib |
|
|
|
|
98.88% |
| AMG-595 Antibody |
|
|
|
|
96.94% |
| Amivantamab (FUT8-KO) |
|
|
|
|
98% |
| AMT-562 |
|
|
|
|
|
| Anbenitamab |
|
|
|
|
99.22% |
| Andamertinib |
|
|
|
|
99.06% |
| Anti-EGFR Antibody (D2C7) |
|
|
|
|
|
| Anti-Epiregulin Antibody |
|
|
|
|
|
| Anti-ERBB1/EGFR/HER1 Antibody |
|
|
|
|
|
| Anti-ERBB3/HER3 (29Z6) |
|
|
|
|
|
| Anti-ERBB3/HER3 (SGP1) |
|
|
|
|
|
| Anti-HER3 Antibody (Ab562) |
|
|
|
|
99.63% |
| Anti-Her4 Antibody |
|
|
|
|
|
| Anti-Human/Mouse Amphiregulin Antibody (AR37) |
|
|
|
|
99.544% |
| Anti-Human/Mouse EGFR Antibody (7A7) |
|
|
|
|
99.45% |
| Anti-Human/Rat HER2 (neu) Antibody (7.16.4) |
|
|
|
|
95.00% |
| Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) |
|
|
|
|
|
| Anti-Mouse EGFR (domain I) Antibody (EMab-300) |
|
|
|
|
|
| Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) |
|
|
|
|
97.589% |
| Anti-Mouse/Human EGFR (domain III) Antibody (EMab-88) |
|
|
|
|
|
| Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) |
|
|
|
|
99.05% |
| anti-NSCLC agent-1 |
|
|
|
|
|
| Anticancer agent 133 |
|
|
|
|
|
| Anticancer agent 158 |
|
|
|
|
|
| Anticancer agent 271 |
|
|
|
|
|
| Anticancer agent 276 |
|
|
|
|
|
| Anticancer agent 69 |
|
|
|
|
|
| Antiproliferative agent-34 |
|
|
|
|
|
| Antiproliferative agent-49 |
|
|
|
|
|
| Antiproliferative agent-54 |
|
|
|
|
|
| Antitumor agent-213 |
|
|
|
|
|
| Anvatabart |
|
|
|
|
98.15% |
| AP4-43 |
|
|
|
|
|
| Apoptosis inducer 35 |
|
|
|
|
|
| Asandeutertinib |
|
|
|
|
99.75% |
| AST5902 |
|
|
|
|
|
| AST5902 trimesylate |
|
|
|
|
98.75% |
| AST5902 mesylate |
|
|
|
|
|
| Asterriquinone |
|
|
|
|
|
| Astragaloside VI |
|
|
|
|
99.95% |
| AV-412 |
|
|
|
|
98.58% |
| AV-412 free base |
|
|
|
|
98.10% |
| AVID100 Antibody |
|
|
|
|
|
| Avitinib |
|
|
|
|
99.95% |
| Avitinib maleate dihydrate |
|
|
|
|
|
| AZ-5104 |
|
|
|
|
99.91% |
| AZ-5104-d2 |
|
|
|
|
|
| AZ14133346 |
|
|
|
|
|
| AZ14240475 |
|
|
|
|
|
| AZ14289671 |
|
|
|
|
|
| AZ5385 |
|
|
|
|
|
| AZ7550 |
|
|
|
|
97.09% |
| AZ7550 hydrochloride |
|
|
|
|
|
| AZ7550 Mesylate |
|
|
|
|
98.70% |
| AZ7550-d5 |
|
|
|
|
|
| Azerutamig |
|
|
|
|
|
| BAT1006 |
|
|
|
|
|
| BAY 2476568 |
|
|
|
|
99.88% |
| BB-1701 |
|
|
|
|
98.81% |
| BBT-176 |
|
|
|
|
98.98% |
| BEBT-109 |
|
|
|
|
98.61% |
| Becotatug |
|
|
|
|
99.00% |
| Becotatug vedotin |
|
|
|
|
96.99% |
| Befotertinib |
|
|
|
|
99.86% |
| Befotertinib mesylate |
|
|
|
|
|
| BGB-102 |
|
|
|
|
99.52% |
| BI-1622 |
|
|
|
|
98.02% |
| BI-4020 |
|
|
|
|
99.30% |
| BI-4142 |
|
|
|
|
98.02% |
| BI-4732 |
|
|
|
|
99.30% |
| BI-8128 |
|
|
|
|
|
| BIBX 1382 dihydrochloride |
|
|
|
|
|
| BIEGi-1 |
|
|
|
|
|
| BIM-46174 |
|
|
|
|
|
| Biotin HER-2 substrate peptide |
|
|
|
|
|
| Biotin-H10 |
|
|
|
|
98.94% |
| BL-B01D1 |
|
|
|
|
99.65% |
| BLU-945 |
|
|
|
|
99.61% |
| BML-265 |
|
|
|
|
|
| BMS-599626 |
|
|
|
|
98.56% |
| BMS-599626 dihydrochloride |
|
|
|
|
|
| BMS-599626 Hydrochloride |
|
|
|
|
98.90% |
| BMS-690514 |
|
|
|
|
99.68% |
| BPI-15086 |
|
|
|
|
|
| BPIQ-I |
|
|
|
|
|
| BPIQ-II hydrochloride |
|
|
|
|
|
| BPN-01 |
|
|
|
|
|
| Brigatinib A |
|
|
|
|
|
| Broussoflavonol F |
|
|
|
|
95.49% |
| BSI-001 |
|
|
|
|
|
| c-Met-IN-31 |
|
|
|
|
|
| Calotatug |
|
|
|
|
98% |
| Calotatug ginistinag |
|
|
|
|
95.94% |
| Candidalysin |
|
|
|
|
99.81% |
| Canertinib |
|
|
|
|
99.74% |
| Caxmotabart |
|
|
|
|
96.56% |
| CCT365623 hydrochloride |
|
|
|
|
98.07% |
| CDK9-IN-41 |
|
|
|
|
98.84% |
| CDX-3379 |
|
|
|
|
99.38% |
| Cetuximab (PBS) |
|
|
|
|
99.33% |
| Cetuximab MMAE |
|
|
|
|
99.64% |
| Cetuximab sarotalocan |
|
|
|
|
|
| CGP-59326 |
|
|
|
|
|
| CGP52411 |
|
|
|
|
99.55% |
| CH401 peptide |
|
|
|
|
|
| CH7233163 |
|
|
|
|
99.41% |
| CHMFL-EGFR-202 |
|
|
|
|
99.75% |
| CHNQD-01281 |
|
|
|
|
|
| Cinrebafusp alfa |
|
|
|
|
98.53% |
| CL-387785 |
|
|
|
|
99.31% |
| CLK1/4-IN-2 |
|
|
|
|
|
| CLM3 |
|
|
|
|
|
| CN009543V |
|
|
|
|
99.37% |
| CNX-2006 |
|
|
|
|
98.00% |
| Corylifol C |
|
|
|
|
|
| COVA208 |
|
|
|
|
|
| COX/5-LO-IN-2 |
|
|
|
|
|
| CP-724714 |
|
|
|
|
98.72% |
| Ctx-L3 |
|
|
|
|
|
| CUDC-101 |
|
|
|
|
99.05% |
| Cyclic(YCDGFYACYMDV) |
|
|
|
|
|
| Cyclo(KLARLLT) |
|
|
|
|
|
| Cyclo[K(N3)larllt] |
|
|
|
|
|
| Cys-GE11 |
|
|
|
|
98.03% |
| CZC-8004 |
|
|
|
|
99.81% |
| CZY43 |
|
|
|
|
|
| D-69491 hydrochloride |
|
|
|
|
|
| DA-0157 |
|
|
|
|
99.59% |
| Dacomitinib hydrate |
|
|
|
|
99.54% |
| Dacomitinib metabolite M1/2 |
|
|
|
|
|
| Dalmitamig |
|
|
|
|
97.158% |
| DDC-01-163 |
|
|
|
|
99.05% |
| DDC4002 |
|
|
|
|
|
| Degalactotigonin |
|
|
|
|
|
| Depatuxizumab |
|
|
|
|
99.58% |
| Depatuxizumab mafodotin |
|
|
|
|
96.18% |
| Depatuxizumab MMAE |
|
|
|
|
99.73% |
| Derazantinib dihydrochloride |
|
|
|
|
|
| DHFR-IN-4 |
|
|
|
|
99.19% |
| DL149 |
|
|
|
|
|
| Dosimertinib-d3 |
|
|
|
|
|
| DOTA-WC8 |
|
|
|
|
|
| DP-C-4 |
|
|
|
|
98.15% |
| DPPY |
|
|
|
|
|
| DS06652923 |
|
|
|
|
|
| DS08701581 |
|
|
|
|
|
| DS21360717 |
|
|
|
|
99.80% |
| DSPE-PEG1000-GE11 |
|
|
|
|
|
| DSPE-PEG2000-GE11 |
|
|
|
|
95.29% |
| DSPE-PEG3400-GE11 |
|
|
|
|
|
| DSPE-PEG5000-GE11 |
|
|
|
|
|
| Dual Galectin-3/EGFR-IN-1 |
|
|
|
|
|
| Dulpatatug |
|
|
|
|
99.09% |
| Dyrk1A-IN-15 |
|
|
|
|
|
| Dyrk1A-IN-16 |
|
|
|
|
|
| DZD1516 |
|
|
|
|
99.62% |
| E260 |
|
|
|
|
99.92% |
| EAI001 |
|
|
|
|
99.93% |
| EAI045 |
|
|
|
|
99.06% |
| EBE-A22 |
|
|
|
|
99.76% |
| EG31 |
|
|
|
|
|
| EGA |
|
|
|
|
99.76% |
| EGFR C797S Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR C797S/L858R Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d746-750 Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d746-750/C797S Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d747-749/A750P Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d747-752/P753S Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR d752-759 Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR G719C Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR G719S Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR Human Pre-designed siRNA Set A |
|
|
|
|
|
| EGFR kinase inhibitor 1 |
|
|
|
|
|
| EGFR kinase inhibitor 2 |
|
|
|
|
|
| EGFR kinase inhibitor 3 |
|
|
|
|
99.03% |
| EGFR kinase inhibitor 4 |
|
|
|
|
|
| EGFR kinase inhibitor 5 |
|
|
|
|
|
| EGFR kinase inhibitor 6 |
|
|
|
|
|
| EGFR kinase inhibitor 7 |
|
|
|
|
|
| EGFR kinase-IN-8 |
|
|
|
|
|
| EGFR L718Q Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR L858R Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR L861Q Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR ligand-10 |
|
|
|
|
|
| EGFR ligand-11 |
|
|
|
|
|
| EGFR ligand-14 |
|
|
|
|
|
| EGFR ligand-14-PEG3-Boc |
|
|
|
|
|
| EGFR ligand-15 |
|
|
|
|
|
| EGFR ligand-18 |
|
|
|
|
|
| EGFR ligand-2 |
|
|
|
|
|
| EGFR ligand-9 |
|
|
|
|
98.80% |
| EGFR Ligand-Linker Conjugates 1 |
|
|
|
|
|
| EGFR Ligand-Linker Conjugates 4 |
|
|
|
|
|
| Egfr Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| EGFR mutant-IN-1 |
|
|
|
|
|
| EGFR mutant-IN-2 |
|
|
|
|
97.0% |
| EGFR Protein Tyrosine Kinase Substrate |
|
|
|
|
99.46% |
| Egfr Rat Pre-designed siRNA Set A |
|
|
|
|
|
| EGFR T790M Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR T790M/FAK-IN-1 |
|
|
|
|
|
| EGFR T790M/FAK-IN-2 |
|
|
|
|
|
| EGFR T790M/L858R Recombinant Human Active Protein Kinase |
|
|
|
|
|
| EGFR T790M/L858R-IN-2 |
|
|
|
|
99.66% |
| EGFR T790M/L858R-IN-3 |
|
|
|
|
|
| EGFR T790M/L858R-IN-4 |
|
|
|
|
|
| EGFR T790M/L858R-IN-5 |
|
|
|
|
|
| EGFR T790M/L858R-IN-6 |
|
|
|
|
|
| EGFR T790M/L858R-IN-7 |
|
|
|
|
|
| EGFR T790M/L858R-IN-8 |
|
|
|
|
99.20% |
| EGFR T790M/L858R-IN-9 |
|
|
|
|
|
| EGFR T790M/VEGFR-2-IN-1 |
|
|
|
|
|
| EGFR WT/T790M-IN-1 |
|
|
|
|
|
| EGFR WT/T790M-IN-2 |
|
|
|
|
|
| EGFR WT/T790M-IN-3 |
|
|
|
|
|
| EGFR WT/T790M-IN-4 |
|
|
|
|
|
| EGFR WT/T790M/L858R-IN-1 |
|
|
|
|
|
| EGFR-IN-1 |
|
|
|
|
|
| EGFR-IN-1 hydrochloride |
|
|
|
|
|
| EGFR-IN-1 TFA |
|
|
|
|
99.38% |
| EGFR-IN-100 |
|
|
|
|
|
| EGFR-IN-101 |
|
|
|
|
|
| EGFR-IN-102 |
|
|
|
|
|
| EGFR-IN-103 |
|
|
|
|
|
| EGFR-IN-104 |
|
|
|
|
|
| EGFR-IN-105 |
|
|
|
|
|
| EGFR-IN-106 |
|
|
|
|
|
| EGFR-IN-107 |
|
|
|
|
|
| EGFR-IN-108 |
|
|
|
|
|
| EGFR-IN-108 chloride |
|
|
|
|
|
| EGFR-IN-109 |
|
|
|
|
|
| EGFR-IN-11 |
|
|
|
|
98.76% |
| EGFR-IN-110 |
|
|
|
|
|
| EGFR-IN-112 |
|
|
|
|
|
| EGFR-IN-113 |
|
|
|
|
|
| EGFR-IN-114 |
|
|
|
|
|
| EGFR-IN-115 |
|
|
|
|
|
| EGFR-IN-116 |
|
|
|
|
|
| EGFR-IN-117 |
|
|
|
|
|
| EGFR-IN-118 |
|
|
|
|
|
| EGFR-IN-119 |
|
|
|
|
|
| EGFR-IN-12 |
|
|
|
|
99.60% |
| EGFR-IN-120 |
|
|
|
|
|
| EGFR-IN-121 |
|
|
|
|
|
| EGFR-IN-122 |
|
|
|
|
99.98% |
| EGFR-IN-123 |
|
|
|
|
|
| EGFR-IN-124 |
|
|
|
|
|
| EGFR-IN-126 |
|
|
|
|
|
| EGFR-IN-127 |
|
|
|
|
|
| EGFR-IN-128 |
|
|
|
|
|
| EGFR-IN-129 |
|
|
|
|
|
| EGFR-IN-130 |
|
|
|
|
|
| EGFR-IN-131 |
|
|
|
|
|
| EGFR-IN-132 |
|
|
|
|
|
| EGFR-IN-133 |
|
|
|
|
|
| EGFR-IN-134 |
|
|
|
|
|
| EGFR-IN-135 |
|
|
|
|
|
| EGFR-IN-136 |
|
|
|
|
|
| EGFR-IN-137 |
|
|
|
|
|
| EGFR-IN-138 |
|
|
|
|
|
| EGFR-IN-139 |
|
|
|
|
|
| EGFR-IN-140 |
|
|
|
|
|
| EGFR-IN-141 |
|
|
|
|
|
| EGFR-IN-142 |
|
|
|
|
|
| EGFR-IN-143 |
|
|
|
|
|
| EGFR-IN-144 |
|
|
|
|
|
| EGFR-IN-145 |
|
|
|
|
|
| EGFR-IN-146 |
|
|
|
|
|
| EGFR-IN-147 |
|
|
|
|
|
| EGFR-IN-148 |
|
|
|
|
|
| EGFR-IN-149 |
|
|
|
|
|
| EGFR-IN-15 |
|
|
|
|
96.21% |
| EGFR-IN-150 |
|
|
|
|
|
| EGFR-IN-151 |
|
|
|
|
|
| EGFR-IN-152 |
|
|
|
|
|
| EGFR-IN-153 |
|
|
|
|
|
| EGFR-IN-154 |
|
|
|
|
|
| EGFR-IN-155 |
|
|
|
|
|
| EGFR-IN-156 |
|
|
|
|
|
| EGFR-IN-157 |
|
|
|
|
|
| EGFR-IN-158 |
|
|
|
|
|
| EGFR-IN-159 |
|
|
|
|
|
| EGFR-IN-16 |
|
|
|
|
|
| EGFR-IN-160 |
|
|
|
|
|
| EGFR-IN-161 |
|
|
|
|
|
| EGFR-IN-162 |
|
|
|
|
|
| EGFR-IN-163 |
|
|
|
|
|
| EGFR-IN-164 |
|
|
|
|
|
| EGFR-IN-165 |
|
|
|
|
|
| EGFR-IN-166 |
|
|
|
|
|
| EGFR-IN-167 |
|
|
|
|
|
| EGFR-IN-168 |
|
|
|
|
|
| EGFR-IN-169 |
|
|
|
|
|
| EGFR-IN-17 |
|
|
|
|
98.18% |
| EGFR-IN-170 |
|
|
|
|
|
| EGFR-IN-171 |
|
|
|
|
|
| EGFR-IN-172 |
|
|
|
|
|
| EGFR-IN-173 |
|
|
|
|
|
| EGFR-IN-174 |
|
|
|
|
|
| EGFR-IN-175 |
|
|
|
|
|
| EGFR-IN-176 |
|
|
|
|
|
| EGFR-IN-177 |
|
|
|
|
|
| EGFR-IN-178 |
|
|
|
|
|
| EGFR-IN-179 |
|
|
|
|
|
| EGFR-IN-18 |
|
|
|
|
|
| EGFR-IN-180 |
|
|
|
|
|
| EGFR-IN-181 |
|
|
|
|
|
| EGFR-IN-182 |
|
|
|
|
|
| EGFR-IN-183 |
|
|
|
|
|
| EGFR-IN-184 |
|
|
|
|
|
| EGFR-IN-185 |
|
|
|
|
|
| EGFR-IN-186 |
|
|
|
|
|
| EGFR-IN-187 |
|
|
|
|
|
| EGFR-IN-189 |
|
|
|
|
|
| EGFR-IN-190 |
|
|
|
|
|
| EGFR-IN-191 |
|
|
|
|
|
| EGFR-IN-192 |
|
|
|
|
|
| EGFR-IN-193 |
|
|
|
|
|
| EGFR-IN-194 |
|
|
|
|
|
| EGFR-IN-195 |
|
|
|
|
|
| EGFR-IN-196 |
|
|
|
|
|
| EGFR-IN-197 |
|
|
|
|
|
| EGFR-IN-198 |
|
|
|
|
|
| EGFR-IN-199 |
|
|
|
|
|
| EGFR-IN-2 |
|
|
|
|
|
| EGFR-IN-200 |
|
|
|
|
|
| EGFR-IN-201 |
|
|
|
|
|
| EGFR-IN-202 |
|
|
|
|
|
| EGFR-IN-203 |
|
|
|
|
|
| EGFR-IN-204 |
|
|
|
|
98.57% |
| EGFR-IN-206 |
|
|
|
|
|
| EGFR-IN-207 |
|
|
|
|
|
| EGFR-IN-208 |
|
|
|
|
|
| EGFR-IN-209 |
|
|
|
|
|
| EGFR-IN-21 |
|
|
|
|
|
| EGFR-IN-210 |
|
|
|
|
|
| EGFR-IN-211 |
|
|
|
|
|
| EGFR-IN-212 |
|
|
|
|
|
| EGFR-IN-213 |
|
|
|
|
|
| EGFR-IN-214 |
|
|
|
|
|
| EGFR-IN-22 |
|
|
|
|
|
| EGFR-IN-23 |
|
|
|
|
|
| EGFR-IN-24 |
|
|
|
|
98.71% |
| EGFR-IN-25 |
|
|
|
|
|
| EGFR-IN-27 |
|
|
|
|
|
| EGFR-IN-28 |
|
|
|
|
|
| EGFR-IN-29 |
|
|
|
|
|
| EGFR-IN-3 |
|
|
|
|
|
| EGFR-IN-30 |
|
|
|
|
|
| EGFR-IN-33 |
|
|
|
|
|
| EGFR-IN-34 |
|
|
|
|
|
| EGFR-IN-35 |
|
|
|
|
|
| EGFR-IN-36 |
|
|
|
|
|
| EGFR-IN-37 |
|
|
|
|
|
| EGFR-IN-38 |
|
|
|
|
|
| EGFR-IN-39 |
|
|
|
|
|
| EGFR-IN-40 |
|
|
|
|
|
| EGFR-IN-42 |
|
|
|
|
|
| EGFR-IN-43 |
|
|
|
|
|
| EGFR-IN-44 |
|
|
|
|
|
| EGFR-IN-45 |
|
|
|
|
|
| EGFR-IN-451 |
|
|
|
|
|
| EGFR-IN-46 |
|
|
|
|
|
| EGFR-IN-47 |
|
|
|
|
96.01% |
| EGFR-IN-48 |
|
|
|
|
|
| EGFR-IN-49 |
|
|
|
|
|
| EGFR-IN-5 |
|
|
|
|
99.49% |
| EGFR-IN-50 |
|
|
|
|
|
| EGFR-IN-51 |
|
|
|
|
|
| EGFR-IN-52 |
|
|
|
|
|
| EGFR-IN-53 |
|
|
|
|
|
| EGFR-IN-54 |
|
|
|
|
|
| EGFR-IN-55 |
|
|
|
|
|
| EGFR-IN-56 |
|
|
|
|
|
| EGFR-IN-57 |
|
|
|
|
|
| EGFR-IN-58 |
|
|
|
|
|
| EGFR-IN-59 |
|
|
|
|
|
| EGFR-IN-60 |
|
|
|
|
|
| EGFR-IN-61 |
|
|
|
|
|
| EGFR-IN-62 |
|
|
|
|
|
| EGFR-IN-63 |
|
|
|
|
|
| EGFR-IN-64 |
|
|
|
|
|
| EGFR-IN-67 |
|
|
|
|
|
| EGFR-IN-68 |
|
|
|
|
|
| EGFR-IN-69 |
|
|
|
|
99.58% |
| EGFR-IN-7 |
|
|
|
|
99.59% |
| EGFR-IN-70 |
|
|
|
|
98.03% |
| EGFR-IN-71 |
|
|
|
|
|
| EGFR-IN-73 |
|
|
|
|
|
| EGFR-IN-74 |
|
|
|
|
|
| EGFR-IN-75 |
|
|
|
|
|
| EGFR-IN-77 |
|
|
|
|
|
| EGFR-IN-78 |
|
|
|
|
99.57% |
| EGFR-IN-79 |
|
|
|
|
|
| EGFR-IN-8 |
|
|
|
|
98.01% |
| EGFR-IN-80 |
|
|
|
|
|
| EGFR-IN-81 |
|
|
|
|
|
| EGFR-IN-82 |
|
|
|
|
|
| EGFR-IN-83 |
|
|
|
|
|
| EGFR-IN-84 |
|
|
|
|
|
| EGFR-IN-85 |
|
|
|
|
|
| EGFR-IN-86 |
|
|
|
|
99.92% |
| EGFR-IN-87 |
|
|
|
|
|
| EGFR-IN-87 hydrochloride |
|
|
|
|
98.0% |
| EGFR-IN-88 |
|
|
|
|
|
| EGFR-IN-89 |
|
|
|
|
98.75% |
| EGFR-IN-9 |
|
|
|
|
98.84% |
| EGFR-IN-90 |
|
|
|
|
|
| EGFR-IN-91 |
|
|
|
|
|
| EGFR-IN-92 |
|
|
|
|
|
| EGFR-IN-93 |
|
|
|
|
|
| EGFR-IN-94 |
|
|
|
|
|
| EGFR-IN-95 |
|
|
|
|
98.76% |
| EGFR-IN-96 |
|
|
|
|
|
| EGFR-IN-97 |
|
|
|
|
|
| EGFR-IN-98 |
|
|
|
|
99.12% |
| EGFR-IN-99 |
|
|
|
|
98.09% |
| EGFR-PK/JNK-2-IN-1 |
|
|
|
|
|
| EGFR-TK-IN-1 |
|
|
|
|
|
| EGFR-TK-IN-2 |
|
|
|
|
|
| EGFR-TK-IN-3 |
|
|
|
|
|
| EGFR-TK-IN-4 |
|
|
|
|
99.90% |
| EGFR-TK-IN-5 |
|
|
|
|
|
| EGFR-TK-IN-6 |
|
|
|
|
|
| EGFR/ACK1-IN-1 |
|
|
|
|
98.19% |
| EGFR/Akt-IN-1 |
|
|
|
|
|
| EGFR/AURKB-IN-1 |
|
|
|
|
99.43% |
| EGFR/BRAF-IN-1 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-1 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-2 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-3 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-4 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-5 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-6 |
|
|
|
|
|
| EGFR/BRAFV600E-IN-7 |
|
|
|
|
|
| EGFR/c-Met-IN-1 |
|
|
|
|
|
| EGFR/C797S-IN-1 |
|
|
|
|
|
| EGFR/CA-IX-IN-1 |
|
|
|
|
|
| EGFR/CDK2-IN-1 |
|
|
|
|
|
| EGFR/CDK2-IN-2 |
|
|
|
|
|
| EGFR/CDK2-IN-3 |
|
|
|
|
|
| EGFR/CDK2-IN-4 |
|
|
|
|
|
| EGFR/CDK2-IN-5 |
|
|
|
|
|
| EGFR/COX-2-IN-1 |
|
|
|
|
|
| EGFR/COX-2-IN-2 |
|
|
|
|
|
| EGFR/COX-2-IN-3 |
|
|
|
|
99.76% |
| EGFR/CSC-IN-1 |
|
|
|
|
|
| EGFR/Cytokine-IN-1 |
|
|
|
|
|
| EGFR/DHFR-IN-1 |
|
|
|
|
|
| EGFR/DHFR-IN-2 |
|
|
|
|
|
| EGFR/ErbB-2 inhibitor-1 |
|
|
|
|
|
| EGFR/ErbB-2-IN-2 |
|
|
|
|
99.45% |
| EGFR/ErbB-2/ErbB-4 inhibitor-3 |
|
|
|
|
96.78% |
| EGFR/HDAC-IN-1 |
|
|
|
|
|
| EGFR/HDAC-IN-2 |
|
|
|
|
|
| EGFR/HER2-IN-10 |
|
|
|
|
|
| EGFR/HER2-IN-11 |
|
|
|
|
|
| EGFR/HER2-IN-12 |
|
|
|
|
|
| EGFR/HER2-IN-13 |
|
|
|
|
|
| EGFR/HER2-IN-14 |
|
|
|
|
|
| EGFR/HER2-IN-15 |
|
|
|
|
|
| EGFR/HER2-IN-16 |
|
|
|
|
|
| EGFR/HER2-IN-17 |
|
|
|
|
|
| EGFR/HER2-IN-18 |
|
|
|
|
|
| EGFR/HER2-IN-19 |
|
|
|
|
|
| EGFR/HER2-IN-2 |
|
|
|
|
|
| EGFR/HER2-IN-20 |
|
|
|
|
|
| EGFR/HER2-IN-3 |
|
|
|
|
|
| EGFR/HER2-IN-4 |
|
|
|
|
|
| EGFR/HER2-IN-5 |
|
|
|
|
|
| EGFR/HER2-IN-6 |
|
|
|
|
|
| EGFR/HER2-IN-7 |
|
|
|
|
|
| EGFR/HER2-IN-8 |
|
|
|
|
|
| EGFR/HER2-IN-9 |
|
|
|
|
98.73% |
| EGFR/HER2/CDK9-IN-1 |
|
|
|
|
|
| EGFR/HER2/CDK9-IN-2 |
|
|
|
|
|
| EGFR/HER2/CDK9-IN-3 |
|
|
|
|
|
| EGFR/HER2/DHFR-IN-1 |
|
|
|
|
|
| EGFR/HER2/DHFR-IN-2 |
|
|
|
|
|
| EGFR/HER2/DHFR-IN-3 |
|
|
|
|
|
| EGFR/HER2/TS-IN-1 |
|
|
|
|
|
| EGFR/HER2/TS-IN-2 |
|
|
|
|
|
| EGFR/InhA-IN-1 |
|
|
|
|
|
| EGFR/microtubule-IN-1 |
|
|
|
|
|
| EGFR/PARP-1-IN-1 |
|
|
|
|
|
| EGFR/PI3Kα-IN-1 |
|
|
|
|
|
| EGFR/STAT3-IN-1 |
|
|
|
|
|
| EGFR/tubulin-IN-1 |
|
|
|
|
|
| EGFR/VEGFR2-IN-1 |
|
|
|
|
|
| EGFR/VEGFR2-IN-10 |
|
|
|
|
|
| EGFR/VEGFR2-IN-11 |
|
|
|
|
|
| EGFR/VEGFR2-IN-12 |
|
|
|
|
|
| EGFR/VEGFR2-IN-13 |
|
|
|
|
|
| EGFR/VEGFR2-IN-2 |
|
|
|
|
|
| EGFR/VEGFR2-IN-3 |
|
|
|
|
|
| EGFR/VEGFR2-IN-4 |
|
|
|
|
|
| EGFR/VEGFR2-IN-5 |
|
|
|
|
|
| EGFR/VEGFR2-IN-6 |
|
|
|
|
|
| EGFR/VEGFR2-IN-7 |
|
|
|
|
|
| EGFR/VEGFR2-IN-8 |
|
|
|
|
|
| EGFR/VEGFR2-IN-9 |
|
|
|
|
|
| EGFRvIII peptide (PEPvIII) |
|
|
|
|
|
| EGFRvIII peptide (PEPvIII) TFA |
|
|
|
|
98.73% |
| ELAAWCRWGFLLALLPPGIAG |
|
|
|
|
|
| ELAAWCRWGFLLALLPPGIAG TFA |
|
|
|
|
|
| EMI1 |
|
|
|
|
99.45% |
| EMI48 |
|
|
|
|
99.02% |
| EMI56 |
|
|
|
|
99.36% |
| Emupertinib |
|
|
|
|
99.10% |
| Enozertinib |
|
|
|
|
98.86% |
| Enozertinib hemihydrate |
|
|
|
|
99.98% |
| EP26 |
|
|
|
|
|
| Epertinib |
|
|
|
|
|
| Epertinib hydrochloride |
|
|
|
|
98.15% |
| Epertinib hydrochloride (Standard) |
|
|
|
|
|
| EphB1-IN-1 |
|
|
|
|
99.51% |
| EphB4-IN-1 |
|
|
|
|
|
| Epidermal Growth Factor Receptor Peptide (985-996) |
|
|
|
|
|
| Epitinib |
|
|
|
|
99.95% |
| Epitinib succinate |
|
|
|
|
99.01% |
| Eps8 peptide 327 |
|
|
|
|
|
| ER121 |
|
|
|
|
98.52% |
| ERBB agonist-1 |
|
|
|
|
99.16% |
| ErbB-1/ErbB-2 tyrosine kinase-IN-1 |
|
|
|
|
|
| ErbB-2-binding peptide |
|
|
|
|
99.52% |
| ERBB2 775YVMA776 Recombinant Human Active Protein Kinase |
|
|
|
|
|
| ERBB2 Human Pre-designed siRNA Set A |
|
|
|
|
|
| Erbb2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| ERBB3 Human Pre-designed siRNA Set A |
|
|
|
|
|
| Erbb3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| Erbb3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
| ERBB4 Human Pre-designed siRNA Set A |
|
|
|
|
|
| Erbb4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| Erbb4 Rat Pre-designed siRNA Set A |
|
|
|
|
|
| Erbicin |
|
|
|
|
|
| Erbstatin |
|
|
|
|
|
| Erlotinib-d4 |
|
|
|
|
|
| ES-072 |
|
|
|
|
98.05% |
| Falnidamol |
|
|
|
|
99.41% |
| Fepixnebart |
|
|
|
|
96.46% |
| Ficerafusp alfa |
|
|
|
|
99.71% |
| Fidasimtamab |
|
|
|
|
≥95.0% |
| FIIN-3 |
|
|
|
|
99.01% |
| FRF-06-057 |
|
|
|
|
|
| FS102 |
|
|
|
|
|
| FSK hydrochloride |
|
|
|
|
99.97% |
| G7-18NATE |
|
|
|
|
|
| G7-18NATE TFA |
|
|
|
|
98.06% |
| Gamendazole |
|
|
|
|
99.44% |
| Ganglioside GT1b (bovine) ammonium |
|
|
|
|
98% |
| Ganglioside GT1b (porcine) ammonium |
|
|
|
|
98% |
| GC1118 |
|
|
|
|
99.22% |
| Gefitinib |
|
|
|
|
|
| Gefitinib N-oxide |
|
|
|
|
|
| Gefitinib N-oxide hydrochloride |
|
|
|
|
|
| Gefitinib-based PROTAC 3 |
|
|
|
|
99.98% |
| GePhos1 |
|
|
|
|
98.88% |
| GI261520A |
|
|
|
|
|
| GLUT1/EGFR-IN-1 |
|
|
|
|
99.75% |
| Gly-PEG3-BA |
|
|
|
|
|
| Gozanertinib |
|
|
|
|
98.37% |
| GW2974 |
|
|
|
|
99.16% |
| GW583340 |
|
|
|
|
|
| GW583340 dihydrochloride |
|
|
|
|
|
| GW837016X |
|
|
|
|
|
| H-9 Dihydrochloride |
|
|
|
|
98.98% |
| H2Mab-139 |
|
|
|
|
|
| HB-EGF-IN-1 |
|
|
|
|
|
| HER2-IN-12 |
|
|
|
|
|
| HER2-IN-13 |
|
|
|
|
|
| HER2-IN-14 |
|
|
|
|
|
| HER2-IN-15 |
|
|
|
|
|
| HER2-IN-17 |
|
|
|
|
|
| HER2-IN-18 |
|
|
|
|
|
| HER2-IN-19 |
|
|
|
|
|
| HER2-IN-20 |
|
|
|
|
|
| HER2-IN-21 |
|
|
|
|
|
| HER2-IN-22 |
|
|
|
|
|
| HER2-IN-23 |
|
|
|
|
|
| HER2-IN-5 |
|
|
|
|
|
| HER2-IN-6 |
|
|
|
|
|
| HER2-IN-7 |
|
|
|
|
|
| HER2-IN-8 |
|
|
|
|
|
| HER2-IN-9 |
|
|
|
|
|
| HER2-targeted peptide H10 |
|
|
|
|
|
| HER2-targeted peptide H6F |
|
|
|
|
98.85% |
| HER2/neu (654-662) GP2 |
|
|
|
|
98.26% |
| HER4/HER2-IN-1 |
|
|
|
|
|
| Herceptide |
|
|
|
|
|
| HG-14-10-04 |
|
|
|
|
99.09% |
| HG-5-88-01 |
|
|
|
|
|
| HJM-561 |
|
|
|
|
99.26% |
| HKI-357 |
|
|
|
|
98.10% |
| HKI-357 dimaleate |
|
|
|
|
|
| HLX-22 |
|
|
|
|
99.47% |
| HNPMI |
|
|
|
|
99.57% |
| HS-72 |
|
|
|
|
|
| HSP90-IN-13 |
|
|
|
|
|
| Hsp90-IN-42 |
|
|
|
|
|
| HTI-1511 Antibody |
|
|
|
|
|
| HVH-2930 |
|
|
|
|
96.54% |
| HW12 |
|
|
|
|
|
| HYNIC-H10F |
|
|
|
|
|
| HYNIC-H6F |
|
|
|
|
|
| HyT36 |
|
|
|
|
96.0% |
| HyT36(-Cl) |
|
|
|
|
|
| iAfaPhos1 |
|
|
|
|
|
| IAM1363 |
|
|
|
|
99.40% |
| IBI-334 |
|
|
|
|
98.18% |
| IBI-334 (FUT8-KO) |
|
|
|
|
|
| IGF-1R modulator 1 |
|
|
|
|
|
| Imbotolimod |
|
|
|
|
|
| Imgatuzumab (FUT8-KO) |
|
|
|
|
|
| IMP-Zn |
|
|
|
|
|
| Isocryptotanshinone |
|
|
|
|
98% |
| Isoprocurcumenol |
|
|
|
|
95.41% |
| Izalontamab |
|
|
|
|
99.89% |
| Jaceidin |
|
|
|
|
|
| JBJ-02-112-05 |
|
|
|
|
|
| JBJ-04-125-02 |
|
|
|
|
|
| JBJ-07-149 |
|
|
|
|
99.09% |
| JBJ-09-063 |
|
|
|
|
|
| JBJ-09-063 hydrochloride |
|
|
|
|
98.52% |
| JBJ-09-063 TFA |
|
|
|
|
99.64% |
| JCN037 |
|
|
|
|
99.09% |
| JG26 |
|
|
|
|
98.14% |
| JGK-068S |
|
|
|
|
|
| JND3229 |
|
|
|
|
99.38% |
| JNJ28871063 hydrochloride |
|
|
|
|
98.36% |
| JS04 |
|
|
|
|
|
| KHK-2866 |
|
|
|
|
98.23% |
| KRAS G12D inhibitor 25 |
|
|
|
|
|
| KU004 |
|
|
|
|
|
| Lapatinib-13C215N |
|
|
|
|
|
| Lapatinib-d7 |
|
|
|
|
|
| Laprituximab emtansine |
|
|
|
|
97.66% |
| LARLLT |
|
|
|
|
|
| LARLLT TFA |
|
|
|
|
99.89% |
| Larotinib |
|
|
|
|
99.50% |
| Larotinib mesylate hydrate |
|
|
|
|
98.66% |
| Lavendustin C6 |
|
|
|
|
|
| Lazertinib |
|
|
|
|
99.87% |
| Lazertinib mesylate |
|
|
|
|
99.85% |
| Lazertinib mesylate hydrate |
|
|
|
|
|
| LDC0496 |
|
|
|
|
|
| Len-604 |
|
|
|
|
|
| Lifirafenib |
|
|
|
|
98.01% |
| Lifirafenib maleate |
|
|
|
|
|
| limertinib |
|
|
|
|
99.12% |
| limertinib diTFA |
|
|
|
|
98.96% |
| Losatuxizumab |
|
|
|
|
99.44% |
| LR004 |
|
|
|
|
|
| LS-106 |
|
|
|
|
|
| LSD1/EGFR-IN-1 |
|
|
|
|
|
| Lunaxafusp (His Tag) |
|
|
|
|
|
| LY456236 |
|
|
|
|
99.57% |
| LY456236 free base |
|
|
|
|
|
| Lys-Arg-Thr-Leu-Arg-Arg |
|
|
|
|
|
| Lys-Arg-Thr-Leu-Arg-Arg acetate |
|
|
|
|
|
| Lys-PEG3-BA |
|
|
|
|
|
| Lyso-Monosialoganglioside GM3 |
|
|
|
|
|
| M802 |
|
|
|
|
|
| Mal-Pip-ValCit-PAB-AZ7550 |
|
|
|
|
|
| MAPK-IN-2 |
|
|
|
|
99.66% |
| Masoprocol tetrapivalate |
|
|
|
|
|
| Mavelertinib |
|
|
|
|
99.34% |
| MC-Val-Cit-PAB-Amide-TLR7 agonist 4 |
|
|
|
|
|
| MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic |
|
|
|
|
97.70% |
| MEDI4276 |
|
|
|
|
|
| MEDI4276 Antibody |
|
|
|
|
96.5212% |
| Mefatinib |
|
|
|
|
98.90% |
| Mefatinib free base |
|
|
|
|
99.40% |
| Mefatinib-d6 |
|
|
|
|
|
| Melafolone |
|
|
|
|
|
| Methyl 2,5-dihydroxycinnamate |
|
|
|
|
99.77% |
| MG-3C |
|
|
|
|
|
| MHES0488A |
|
|
|
|
|
| MJ04 |
|
|
|
|
98.08% |
| MM-111 |
|
|
|
|
|
| MM-151 |
|
|
|
|
|
| MP-RM-1 |
|
|
|
|
96.29% |
| MRC-G-001 |
|
|
|
|
|
| MS154 |
|
|
|
|
99.71% |
| MS154N |
|
|
|
|
99.3% |
| MS39 |
|
|
|
|
99.89% |
| MS39N |
|
|
|
|
98.0% |
| MS9427 |
|
|
|
|
95.29% |
| MS9427 TFA |
|
|
|
|
98.38% |
| MS9449 |
|
|
|
|
98.95% |
| MTX-211 |
|
|
|
|
99.81% |
| MTX-211 (Standard) |
|
|
|
|
|
| MTX-216 |
|
|
|
|
|
| MTX-241F |
|
|
|
|
|
| MTX-531 |
|
|
|
|
99.87% |
| Multi-kinase-IN-4 |
|
|
|
|
|
| Multi-kinase-IN-6 |
|
|
|
|
|
| Multi-kinase-IN-7 |
|
|
|
|
|
| Multi-target kinase inhibitor 2 |
|
|
|
|
99.82% |
| Multi-target kinase-IN-7 |
|
|
|
|
|
| Multi-target kinase-IN-8 |
|
|
|
|
|
| Mutated EGFR-IN-2 |
|
|
|
|
|
| Mutated EGFR-IN-3 |
|
|
|
|
|
| Myosin Regulatory Light Chain MRCL3 (11-24) |
|
|
|
|
|
| Lavendustin C |
|
|
|
|
98.17% |
| N-Desmethyl dosimertinib-d5 |
|
|
|
|
|
| N-Methyl-dosimertinib-d5 |
|
|
|
|
|
| N3-PEG8-Phe-Lys-PABC-Gefitinib |
|
|
|
|
|
| N3-PEG8-Phe-Lys-PABC-Gefitinib TFA |
|
|
|
|
|
| Naquotinib |
|
|
|
|
98.10% |
| Naquotinib mesylate |
|
|
|
|
98.06% |
| Nelipepimut-S |
|
|
|
|
|
| Neoschaftoside |
|
|
|
|
98.04% |
| Neptinib |
|
|
|
|
|
| Nezutatug |
|
|
|
|
99.9% |
| NGI-189 |
|
|
|
|
99.29% |
| Nimotuzumab (powder) |
|
|
|
|
|
| NM-02 |
|
|
|
|
|
| NODAGA-NHS |
|
|
|
|
|
| NRC-2694 |
|
|
|
|
99.84% |
| NRC-2694-A |
|
|
|
|
|
| NS-062 |
|
|
|
|
|
| NSC 104999 |
|
|
|
|
|
| NSC 228155 |
|
|
|
|
99.58% |
| NSC 57148 |
|
|
|
|
|
| NSC114126 |
|
|
|
|
|
| NSC381467 |
|
|
|
|
|
| NSC689857 |
|
|
|
|
99.49% |
| NSC81111 |
|
|
|
|
|
| NT-1 |
|
|
|
|
99.40% |
| O-Desmethyl dacomitinib |
|
|
|
|
|
| O-Desmethyl gefitinib |
|
|
|
|
99.40% |
| O-Desmethyl gefitinib-d6 |
|
|
|
|
|
| O-Desmethyl gefitinib-d8 |
|
|
|
|
99.84% |
| ODS-2004436 |
|
|
|
|
|
| OK2 |
|
|
|
|
99.13% |
| Olafertinib |
|
|
|
|
99.51% |
| Oligopeptide-41 |
|
|
|
|
98.05% |
| Olmutinib hydrochloride |
|
|
|
|
|
| Opadotina |
|
|
|
|
|
| Oritinib |
|
|
|
|
99.59% |
| Oritinib mesylate |
|
|
|
|
|
| Os30 |
|
|
|
|
98.34% |
| p-SCN-Bn-NOTA trihydrochloride |
|
|
|
|
99.75% |
| PACAP (1-38), human, ovine, rat |
|
|
|
|
99.99% |
| PACAP (1-38), human, ovine, rat TFA |
|
|
|
|
|
| Paeciloquinone A |
|
|
|
|
|
| Paeciloquinone B |
|
|
|
|
|
| Paeciloquinone C |
|
|
|
|
|
| Paeciloquinone D |
|
|
|
|
|
| Paeciloquinone E |
|
|
|
|
|
| Paeciloquinone F |
|
|
|
|
|
| Pamvatamig |
|
|
|
|
95.298% |
| Pamvatamig (FUT8-KO) |
|
|
|
|
|
| pan-HER-IN-1 |
|
|
|
|
|
| pan-HER-IN-2 |
|
|
|
|
98.10% |
| Panitumumab (powder) |
|
|
|
|
|
| PD 173955 analog 1 |
|
|
|
|
|
| PD 174265 |
|
|
|
|
98.35% |
| PD-089828 |
|
|
|
|
98.07% |
| PD-161570 |
|
|
|
|
99.82% |
| PD153035 |
|
|
|
|
98.56% |
| PD153035 Hydrochloride |
|
|
|
|
99.48% |
| PD158780 |
|
|
|
|
99.47% |
| PD168393 |
|
|
|
|
98.01% |
| PDE5-IN-3 |
|
|
|
|
|
| PDZ1i |
|
|
|
|
99.29% |
| Pebezertinib |
|
|
|
|
99.56% |
| Pertuzumab zuvotolimod |
|
|
|
|
98.64% |
| Pertuzumab-LD3 |
|
|
|
|
|
| Peruvoside |
|
|
|
|
99.32% |
| Perzebertinib |
|
|
|
|
|
| Petosemtamab (FUT8-KO) |
|
|
|
|
99% |
| PF-06459988 |
|
|
|
|
99.10% |
| PF-06672131 |
|
|
|
|
99.47% |
| PF-6274484 |
|
|
|
|
98.76% |
| PF-6422899 |
|
|
|
|
|
| Piperonylic acid |
|
|
|
|
99.94% |
| PKI-166 |
|
|
|
|
98.92% |
| PKI-166 hydrochloride |
|
|
|
|
|
| PKM2/PDK1-IN-1 |
|
|
|
|
|
| PP 3 |
|
|
|
|
99.20% |
| PP487 |
|
|
|
|
|
| pp60 (v-SRC) Autophosphorylation Site, Phosphorylated |
|
|
|
|
|
| pp60v-src Autophosphorylation site |
|
|
|
|
99.93% |
| Pred17 |
|
|
|
|
|
| PRMT5/EGFR-IN-1 |
|
|
|
|
|
| Pro-PEG3-BA |
|
|
|
|
|
| PROTAC EGFR degrader 10 |
|
|
|
|
|
| PROTAC EGFR degrader 11 |
|
|
|
|
99.20% |
| PROTAC EGFR degrader 12 |
|
|
|
|
|
| PROTAC EGFR degrader 13 |
|
|
|
|
|
| PROTAC EGFR degrader 14 |
|
|
|
|
99.26% |
| PROTAC EGFR degrader 15 |
|
|
|
|
99.23% |
| PROTAC EGFR degrader 16 |
|
|
|
|
|
| PROTAC EGFR degrader 17 |
|
|
|
|
|
| PROTAC EGFR degrader 2 |
|
|
|
|
95.09% |
| PROTAC EGFR degrader 3 |
|
|
|
|
97.39% |
| PROTAC EGFR degrader 4 |
|
|
|
|
99.70% |
| PROTAC EGFR degrader 5 |
|
|
|
|
|
| PROTAC EGFR degrader 6 |
|
|
|
|
|
| PROTAC EGFR degrader 7 |
|
|
|
|
99.48% |
| PROTAC EGFR degrader 7 diTFA |
|
|
|
|
97.15% |
| PROTAC EGFR degrader 8 |
|
|
|
|
98.90% |
| PROTAC EGFR degrader 9 |
|
|
|
|
98.35% |
| PROTAC HER2 degrader-1 |
|
|
|
|
98.0% |
| PROTAC Her3 Degrader-8 |
|
|
|
|
99.60% |
| PROTAC Her3-binding moiety 2 |
|
|
|
|
|
| PROTAC PARP/EGFR ligand 1 |
|
|
|
|
|
| Pruvonertinib |
|
|
|
|
99.50% |
| Pyrotinib dimaleate |
|
|
|
|
98.04% |
| REGN-1400 |
|
|
|
|
|
| REGN3124 |
|
|
|
|
|
| rel-Lifirafenib |
|
|
|
|
|
| RET-IN-19 |
|
|
|
|
|
| Rezivertinib |
|
|
|
|
99.62% |
| Rezivertinib hydrochloride |
|
|
|
|
|
| RG 14921 |
|
|
|
|
|
| RG-14467 |
|
|
|
|
|
| RG13022 |
|
|
|
|
96.74% |
| RG14620 |
|
|
|
|
99.02% |
| Rinumafusp alfa |
|
|
|
|
97.09% |
| Rocbrutinib |
|
|
|
|
99.76% |
| Rociletinib |
|
|
|
|
99.67% |
| Rociletinib hydrobromide |
|
|
|
|
98.04% |
| Rolditamig |
|
|
|
|
95.26% |
| RTC-5 |
|
|
|
|
99.37% |
| Runimotamab |
|
|
|
|
99.00% |
| Ruzaltatug |
|
|
|
|
95.69% |
| Sacibertinib |
|
|
|
|
|
| Sapitinib fumarate |
|
|
|
|
|
| SCT200 |
|
|
|
|
99.09% |
| SDZ281-977 |
|
|
|
|
98.00% |
| Sec61-IN-3 |
|
|
|
|
99.22% |
| Selatinib |
|
|
|
|
98.56% |
| Self-assembling peptide pY1 |
|
|
|
|
|
| Sevabertinib |
|
|
|
|
99.90% |
| SG3376 |
|
|
|
|
|
| SH-1092 |
|
|
|
|
|
| SHR-A1201 |
|
|
|
|
97.35% |
| Si306 |
|
|
|
|
|
| SIAIS164018 |
|
|
|
|
|
| SIAIS164018 hydrochloride |
|
|
|
|
98.06% |
| SIBP-03 |
|
|
|
|
|
| Silevertinib |
|
|
|
|
99.74% |
| Simotinib |
|
|
|
|
99.39% |
| Simotinib hydrochloride |
|
|
|
|
|
| SIQ17 |
|
|
|
|
|
| SJF-1521 |
|
|
|
|
99.65% |
| SJF-1528 |
|
|
|
|
98.86% |
| SJF-1528 hemihydrate |
|
|
|
|
98.90% |
| SKLB188 |
|
|
|
|
|
| SKS-927 |
|
|
|
|
|
| SOS1/EGFR-IN-1 |
|
|
|
|
99.54% |
| SOS1/EGFR-IN-2 |
|
|
|
|
|
| SPH5030 |
|
|
|
|
99.40% |
| SRT6 |
|
|
|
|
|
| SSO111 sodium |
|
|
|
|
|
| SSO111 sodium scrambled negative control |
|
|
|
|
|
| SSOe26 sodium |
|
|
|
|
|
| SSOe26 sodium scrambled negative control |
|
|
|
|
|
| SST0116CL1 |
|
|
|
|
|
| ST8155AA1 |
|
|
|
|
|
| STA-013 |
|
|
|
|
99.18% |
| STX-721 |
|
|
|
|
98.25% |
| SU 5402 |
|
|
|
|
|
| SU-4313 |
|
|
|
|
99.31% |
| SU5204 |
|
|
|
|
99.46% |
| Sulforaphene |
|
|
|
|
99.78% |
| Sutetinib |
|
|
|
|
99.27% |
| Sutetinib maleate |
|
|
|
|
|
| Sym004 |
|
|
|
|
98.97% |
| T-1-DOCA |
|
|
|
|
|
| T-1-PMPA |
|
|
|
|
99.70% |
| TAK-285 |
|
|
|
|
98.99% |
| Tarlox-TKI |
|
|
|
|
98.79% |
| Tarloxotinib bromide |
|
|
|
|
98.75% |
| TAS-121 |
|
|
|
|
|
| TAS0728 |
|
|
|
|
99.71% |
| TAS2940 |
|
|
|
|
|
| TAS2940 fumarate |
|
|
|
|
|
| TAT-327 |
|
|
|
|
|
| Tesevatinib |
|
|
|
|
99.41% |
| Tesevatinib tosylate |
|
|
|
|
|
| Theliatinib tartrate |
|
|
|
|
|
| Theophylline-platinum(IV) prodrug-1 |
|
|
|
|
|
| Tilatamig |
|
|
|
|
99.99% |
| Tilatamig samrotecan |
|
|
|
|
95.26% |
| Topoisomerase II/EGFR-IN-1 |
|
|
|
|
|
| Topoisomerase II/EGFR-IN-2 |
|
|
|
|
|
| Trastuzumab (anti-HER2) |
|
|
|
|
99.838% |
| Trastuzumab deruxtecan |
|
|
|
|
99.50% |
| Trastuzumab deruxtecan (solution) |
|
|
|
|
98.20% |
| Trastuzumab emtansine (solution) |
|
|
|
|
98.27% |
| Trastuzumab envedotin |
|
|
|
|
|
| Trastuzumab rezetecan |
|
|
|
|
|
| Trastuzumab vedotin |
|
|
|
|
98.05% |
| TrxR/EGFR-IN-1 |
|
|
|
|
|
| Tubulin-IN-64 |
|
|
|
|
|
| Tucatinib |
|
|
|
|
99.48% |
| Tucatinib hemiethanolate |
|
|
|
|
98.82% |
| Tucatinib-d6 |
|
|
|
|
|
| Turigrobart |
|
|
|
|
99.9% |
| Tuxobertinib |
|
|
|
|
99.88% |
| TX-1123 |
|
|
|
|
|
| TX1-85-1 |
|
|
|
|
99.65% |
| TX2-120-1 |
|
|
|
|
|
| TX2-121-1 |
|
|
|
|
|
| Tyrosine kinase-IN-7 |
|
|
|
|
99.25% |
| Tyrphostin 23 |
|
|
|
|
98.19% |
| Tyrphostin 25 |
|
|
|
|
99.00% |
| Tyrphostin 63 |
|
|
|
|
|
| Tyrphostin 8 |
|
|
|
|
98.0% |
| Tyrphostin A51 |
|
|
|
|
99.0% |
| Tyrphostin AG 112 |
|
|
|
|
98.31% |
| Tyrphostin AG 528 |
|
|
|
|
98.0% |
| Tyrphostin AG 879 |
|
|
|
|
99.26% |
| Tyrphostin AG213 |
|
|
|
|
|
| Tyrphostin AG30 |
|
|
|
|
98.51% |
| TYVPANASL TFA |
|
|
|
|
|
| TZEP7 |
|
|
|
|
|
| Umizortamig |
|
|
|
|
96.90% |
| UNC-CA359 |
|
|
|
|
|
| Urolithin M5 |
|
|
|
|
97.31% |
| Vadalentamig |
|
|
|
|
95.29% |
| Varlitinib |
|
|
|
|
98.66% |
| Varlitinib tosylate |
|
|
|
|
|
| Varzutamig |
|
|
|
|
|
| VEGFR-2/c-Met/EGFR-IN-1 |
|
|
|
|
|
| VEGFR-IN-1 |
|
|
|
|
99.07% |
| VEGFR-IN-4 |
|
|
|
|
|
| Vislarafusp alfa |
|
|
|
|
98.98% |
| WB-308 |
|
|
|
|
|
| WGYRGFYC |
|
|
|
|
|
| WHI-P154 |
|
|
|
|
98.77% |
| WHI-P180 |
|
|
|
|
99.84% |
| WHI-P180 hydrochloride |
|
|
|
|
|
| Wighteone |
|
|
|
|
98.71% |
| Wnt/β-catenin-IN-6 |
|
|
|
|
98.34% |
| WS6 |
|
|
|
|
99.09% |
| WZ-3146 |
|
|
|
|
99.28% |
| WZ4002 |
|
|
|
|
98.99% |
| WZ8040 |
|
|
|
|
98.29% |
| XYD049 |
|
|
|
|
99.46% |
| YS-363 |
|
|
|
|
99.52% |
| YS-67 |
|
|
|
|
99.41% |
| Yuanhuadin |
|
|
|
|
|
| Z118332870 |
|
|
|
|
|
| Zalutumumab (powder) |
|
|
|
|
|
| ZD-4190 |
|
|
|
|
98.08% |
| Zipalertinib |
|
|
|
|
99.62% |
| ZJY-54 |
|
|
|
|
|
| ZM 449829 |
|
|
|
|
99.73% |
| ZM-306416 hydrochloride |
|
|
|
|
|
| ZNL-0056 |
|
|
|
|
|
| Zorifertinib |
|
|
|
|
99.37% |
| Zorifertinib hydrochloride |
|
|
|
|
|
| ZSH-2117 |
|
|
|
|
|
| ZW-49 |
|
|
|
|
|
| β-Hydroxyisovalerylshikonin |
|
|
|
|
99.83% |
| Lapatinib ditosylate |
|
|
|
|
99.98% |
| Lapatinib ditosylate monohydrate |
|
|
|
|
99.99% |
| Inetetamab |
|
|
|
|
96.54% |
| Imgatuzumab |
|
|
|
|
99.41% |
| Futuximab |
|
|
|
|
98.09% |
| Firmonertinib |
|
|
|
|
99.89% |
| Elgemtumab |
|
|
|
|
99.00% |
| Hexachlorobenzene |
|
|
|
|
98.82% |
| Pimurutamab |
|
|
|
|
99.42% |
| Flavokawain C |
|
|
|
|
99.53% |
| Canertinib dihydrochloride |
|
|
|
|
99.68% |
| Afatinib-d6 dimaleate |
|
|
|
|
|
| Gefitinib-d3 |
|
|
|
|
98.39% |
| Gefitinib-d8 |
|
|
|
|
98.42% |
| Gefitinib-d6 |
|
|
|
|
98.0% |
| Gefitinib |
|
|
|
|
99.99% |
| Gefitinib dihydrochloride |
|
|
|
|
|
| Gefitinib impurity 2 |
|
|
|
|
99.56% |
| Pyrotinib |
|
|
|
|
99.89% |
| Furanodienone |
|
|
|
|
99.90% |
| Khellin |
|
|
|
|
99.66% |
| Tubeimoside II |
|
|
|
|
99.90% |
| Amivantamab |
|
|
|
|
99.90% |
| Icotinib |
|
|
|
|
99.92% |
| Erlotinib (Standard) |
|
|
|
|
99.97% |
| Erlotinib-13C6 |
|
|
|
|
|
| Erlotinib-d6 |
|
|
|
|
99.83% |
| Erlotinib-d8 |
|
|
|
|
|
| Erlotinib |
|
|
|
|
99.96% |
| Erlotinib mesylate |
|
|
|
|
|
| Pelitinib-d6 |
|
|
|
|
|
| Pelitinib |
|
|
|
|
98.52% |
| Chrysophanol (Standard) |
|
|
|
|
97% |
| Chrysophanol |
|
|
|
|
99.66% |
| Osimertinib-13C,d3 |
|
|
|
|
|
| Osimertinib-d6 |
|
|
|
|
99.64% |
| Dosimertinib-d5 mesylate |
|
|
|
|
99.50% |
| Osimertinib |
|
|
|
|
99.69% |
| Osimertinib dimesylate |
|
|
|
|
99.00% |
| Osimertinib mesylate |
|
|
|
|
99.97% |
| Olmutinib |
|
|
|
|
99.49% |
| Nimotuzumab |
|
|
|
|
96.80% |
| Camelliaside A |
|
|
|
|
99.65% |
| Bafisontamab |
|
|
|
|
99.9% |
| Pertuzumab |
|
|
|
|
99.8% |
| Pertuzumab (anti-HER2) |
|
|
|
|
99.10% |
| Panitumumab (anti-EGFR) |
|
|
|
|
99.02% |
| Panitumumab |
|
|
|
|
99.77% |
| Patritumab |
|
|
|
|
99.28% |
| Coprelotamab |
|
|
|
|
|
| Duligotuzumab |
|
|
|
|
99.17% |
| Serclutamab |
|
|
|
|
99.97% |
| Modotuximab |
|
|
|
|
99.08% |
| Zalutumumab |
|
|
|
|
98.34% |
| Tomuzotuximab |
|
|
|
|
≥99.0% |
| Laprituximab |
|
|
|
|
99.74% |
| Lapatinib |
|
|
|
|
99.83% |
| Lapatinib-d7 dihydrochloride |
|
|
|
|
|
| Lapatinib-13C,d7 |
|
|
|
|
|
| Lapatinib-d4 |
|
|
|
|
99.02% |
| Lapatinib-d4-1 |
|
|
|
|
|
| Lapatinib-d5 |
|
|
|
|
|
| Ontuxizumab |
|
|
|
|
99.85% |
| Trastuzumab emtansine |
|
|
|
|
98.54% |
| Trastuzumab |
|
|
|
|
99.80% |
| Timigutuzumab |
|
|
|
|
97.53% |
| Mubritinib |
|
|
|
|
99.86% |
| Neratinib |
|
|
|
|
99.94% |
| Neratinib-d6 |
|
|
|
|
|
| Cyasterone |
|
|
|
|
99.58% |
| Genistein-d4 |
|
|
|
|
98.81% |
| Genistein (Standard) |
|
|
|
|
98.70% |
| Genistein |
|
|
|
|
99.82% |
| Delphinidin chloride |
|
|
|
|
98.0% |
| Delphinidin 3-glucoside chloride |
|
|
|
|
99.89% |
| Sapitinib |
|
|
|
|
99.93% |
| Poziotinib |
|
|
|
|
99.96% |
| Zenocutuzumab |
|
|
|
|
99.9% |
| Zanidatamab |
|
|
|
|
98.56% |
| Petosemtamab |
|
|
|
|
99.94% |
| Tephrosin |
|
|
|
|
98.02% |
| Margetuximab |
|
|
|
|
≥99.0% |
| Daphnetin |
|
|
|
|
99.77% |
| Seribantumab |
|
|
|
|
96.043% |
| Gancotamab antibody |
|
|
|
|
≥99.0% |
| Firmonertinib-d3 mesylate |
|
|
|
|
99.00% |
| Firmonertinib mesylate |
|
|
|
|
99.97% |
| Lapatinib tosylate |
|
|
|
|
|
| Lapatinib-d4 tosylate |
|
|
|
|
|
| Gefitinib hydrochloride |
|
|
|
|
99.77% |
| Icotinib Hydrochloride |
|
|
|
|
99.63% |
| Erlotinib Hydrochloride |
|
|
|
|
99.94% |
| Erlotinib Hydrochloride (Standard) |
|
|
|
|
99.73% |
| Erlotinib-d6 hydrochloride |
|
|
|
|
98.13% |
| Erlotinib-13C6 hydrochloride |
|
|
|
|
|
| AG-1478 hydrochloride |
|
|
|
|
|
| Almonertinib hydrochloride |
|
|
|
|
98.92% |
| Clitorin |
|
|
|
|
99.45% |
| Corosolic acid |
|
|
|
|
99.89% |
| Butein |
|
|
|
|
99.64% |
| Vesencumab |
|
|
|
|
99.34% |
| Disitamab vedotin |
|
|
|
|
98.90% |
| Voacamine |
|
|
|
|
99.64% |
| Necitumumab |
|
|
|
|
99.90% |
| Myristicin |
|
|
|
|
99.54% |
| Sunvozertinib |
|
|
|
|
99.62% |
| Allitinib tosylate |
|
|
|
|
99.54% |
| Istiratumab |
|
|
|
|
98.45% |
| Etevritamab |
|
|
|
|
97.00% |
| Avitinib maleate |
|
|
|
|
99.86% |
| Mobocertinib |
|
|
|
|
99.60% |
| Mobocertinib succinate |
|
|
|
|
99.83% |
| Mobocertinib mesylate |
|
|
|
|
|
| Cucurbitacin IIa |
|
|
|
|
99.90% |
| Lavendustin A |
|
|
|
|
98.95% |
| Theliatinib |
|
|
|
|
99.72% |
| Cetuximab |
|
|
|
|
99.81% |
| Coenzyme Q0 |
|
|
|
|
99.79% |
| Dacomitinib-d10 dihydrochloride |
|
|
|
|
|
| Dacomitinib-d10 |
|
|
|
|
|
| Dacomitinib |
|
|
|
|
99.74% |
| Disitamab |
|
|
|
|
98.73% |
| Disitamab (powder) |
|
|
|
|
98.44% |
| Nazartinib |
|
|
|
|
99.53% |
| Nazartinib S-enantiomer |
|
|
|
|
95.10% |
| Nazartinib mesylate |
|
|
|
|
|
| AG-1478 |
|
|
|
|
99.57% |
| Afatinib |
|
|
|
|
99.92% |
| Afatinib-d4 |
|
|
|
|
|
| Afatinib-d6 |
|
|
|
|
99.0% |
| Afatinib dimaleate |
|
|
|
|
99.74% |
| Almonertinib |
|
|
|
|
99.83% |
| Almonertinib-d6 |
|
|
|
|
|
| Almonertinib mesylate |
|
|
|
|
99.67% |
| Matuzumab |
|
|
|
|
98.12% |
| Neratinib maleate |
|
|
|
|
99.74% |
| Lumretuzumab |
|
|
|
|
≥99.0% |